Top

Gepubliceerd in:

05-04-2023

Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03

Auteurs: Thomas M. Atkinson, Shelly Lensing, Jeannette Y. Lee, Di Chang, Soo Young Kim, Yuelin Li, Kathleen A. Lynch, Andrew Webb, Susan M. Holland, Erica I. Lubetkin, Stephen Goldstone, Mark H. Einstein, Elizabeth A. Stier, Dorothy J. Wiley, Ronald Mitsuyasu, Isabella Rosa-Cunha, David M. Aboulafia, Shireesha Dhanireddy, Jeffrey T. Schouten, Rebecca Levine, Edward Gardner, Jeffrey Logan, Hillary Dunleavy, Luis F. Barroso, Gary Bucher, Jessica Korman, Benjamin Stearn, Timothy J. Wilkin, Grant Ellsworth, Julia C. Pugliese, Abigail Arons, Jack E. Burkhalter, David Cella, J. Michael Berry-Lawhorn, Joel M. Palefsky

Gepubliceerd in: Quality of Life Research | Uitgave 8/2023

Abstract

Purpose

To determine whether treatment of anal high-grade squamous intraepithelial lesions (HSIL), vs active monitoring, is effective in reducing incidence of anal cancer in persons living with HIV, the US National Cancer Institute funded the Phase III ANal Cancer/HSIL Outcomes Research (ANCHOR) clinical trial. As no established patient-reported outcomes (PRO) tool exists for persons with anal HSIL, we sought to estimate the construct validity and responsiveness of the ANCHOR Health-Related Symptom Index (A-HRSI).

Methods

The construct validity phase enrolled ANCHOR participants who were within two weeks of randomization to complete A-HRSI and legacy PRO questionnaires at a single time point. The responsiveness phase enrolled a separate cohort of ANCHOR participants who were not yet randomized to complete A-HRSI at three time points: prior to randomization (T1), 14–70 (T2), and 71–112 (T3) days following randomization.

Results

Confirmatory factor analysis techniques established a three-factor model (i.e., physical symptoms, impact on physical functioning, impact on psychological functioning), with moderate evidence of convergent validity and strong evidence of discriminant validity in the construct validity phase (n = 303). We observed a significant moderate effect for changes in A-HRSI impact on physical functioning (standardized response mean = 0.52) and psychological symptoms (standardized response mean = 0.60) from T2 (n = 86) to T3 (n = 92), providing evidence of responsiveness.

Conclusion

A-HRSI is a brief PRO index that captures health-related symptoms and impacts related to anal HSIL. This instrument may have broad applicability in other contexts assessing individuals with anal HSIL, which may ultimately help improve clinical care and assist providers and patients with medical decision-making.

vorige artikel Measuring Frailty Using Patient-Reported Outcomes (PRO) Data: A Feasibility Study in Patients with Multiple Myeloma

volgende artikel Development and validation of a measure of adolescent and young adult goal-based quality of life (MAYA-GQOL)

Goedert, J. J., Hosgood, H. D., Biggar, R. J., Strickler, H. D., & Rabkin, C. S. (2016). Screening for cancer in persons living with HIV infection. Trends in Cancer, 2(8), 416–428. https://doi.org/10.1016/j.trecan.2016.06.007. PubMed PMID: 27891533; PubMed Central PMCID: PMC5120729.CrossRefPubMedPubMedCentral

Shiels, M. S., Islam, J. Y., Rosenberg, P. S., Hall, H. I., Jacobson, E., & Engels, E. A. (2018). Projected cancer incidence rates and burden of incident cancer cases in HIV-infected adults in the United States through 2030. Annals of Internal Medicine, 168(12), 866–73. https://doi.org/10.7326/M17-2499. PubMed PMID: 29801099; PubMed Central PMCID: PMC6329294.CrossRefPubMedPubMedCentral

Howlader, N., Noone, A. M., Krapcho, M., Miller, D., Brest, A., Yu, M., et al. SEER cancer statistics review, 1975–2019, National Cancer Institute. Bethesda, MD based on Nov 2021 SEER data submission, posted to the SEER web site, April 2022. Retrieved July 27, 2022, from https://seer.cancer.gov/statistics-network/explorer/application.html

Wang, C. J., & Palefsky, J. M. (2019). HPV-associated anal cancer in the HIV/AIDS patient. Cancer Treatment Research, 177, 183–209. https://doi.org/10.1007/978-3-030-03502-0_7. PubMed PMID: 30523625.CrossRefPubMed

St Laurent, J., Luckett, R., & Feldman, S. (2018). HPV vaccination and the effects on rates of HPV-related cancers. Current Problems in Cancer., 42(5), 493–506. https://doi.org/10.1016/j.currproblcancer.2018.06.004. PubMed PMID: 30041818.CrossRefPubMed

Meites, E., Szilagyi, P. G., Chesson, H. W., Unger, E. R., Romero, J. R., & Markowitz, L. E. (2019). Human papillomavirus vaccination for adults: Updated recommendations of the advisory committee on immunization practices. Morbidity and Mortality Weekly Report, 68(32), 698–702. https://doi.org/10.15585/mmwr.mm6832a3. PubMed PMID: 31415491; PubMed Central PMCID: PMC6818701.CrossRefPubMedPubMedCentral

Palefsky, J. M. (2015). Screening to prevent anal cancer: Current thinking and future directions. Cancer Cytopathology., 123(9), 509–510.CrossRefPubMed

Palefsky, J. M. (2017). Human papillomavirus-associated anal and cervical cancers in HIV-infected individuals: Incidence and prevention in the antiretroviral therapy era. Current Opinion in HIV AIDS, 12(1), 26–30. https://doi.org/10.1097/COH.0000000000000336. PubMed PMID: 27828801; PubMed Central PMCID: PMC5292043.CrossRefPubMed

Koskan, A. M., Brennhofer, S. A., & Helitzer, D. L. (2019). Screening for anal cancer precursors among patients living with HIV in the absence of national guidelines: Practitioners’ perspectives. Cancer Causes Control, 30(9), 989–96. https://doi.org/10.1007/s10552-019-01209-8. PubMed PMID: 31302838.CrossRefPubMed

10.

Palefsky, J. M., & Cranston, R. D. (2017). Anal squamous intraepithelial lesions: Diagnosis, screening, prevention, and treatment. UpToDate Inc.

11.

US Department of Health and Human Services. (2009, Dec). Guidance for industry. Patient-reported outcome measures: Use in medical product development to support labeling claims. Retrieved July 27, 2022, from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf

12.

Haslam, A., Herrera-Perez, D., Gill, J., & Prasad, V. (2020). Patient experience captured by quality-of-life measurement in oncology clinical trials. JAMA Network Open., 3(3), e200363. https://doi.org/10.1001/jamanetworkopen.2020.0363. PubMed PMID: 32129865; PubMed Central PMCID: PMC7057133.CrossRefPubMedPubMedCentral

13.

Cella, D., Wagner, L., Cashy, J., Hensing, T. A., Yount, S., & Lilenbaum, R. C. (2007). Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. Journal of the National Cancer Institute Monographs., 37, 53–60. https://doi.org/10.1093/jncimonographs/lgm009. PubMed PMID: 17951232.CrossRef

14.

Ganz, P. A. (1994). Long-range effect of clinical trial interventions on quality of life. Cancer, 74(S9), 2620–2624. https://doi.org/10.1002/1097-0142(19941101)74:9CrossRefPubMed

15.

Basch, E. (2016). Missing patients’ symptoms in cancer care delivery-the importance of patient-reported outcomes. JAMA Oncology, 2(4), 433–4. https://doi.org/10.1001/jamaoncol.2015.4719. PubMed PMID: 26720842.CrossRefPubMed

16.

Basch, E. (2017). Patient-reported outcomes—Harnessing patients’ voices to improve clinical care. N Engl J Med., 376(2), 105–8. https://doi.org/10.1056/NEJMp1611252. PubMed PMID: 28076708.CrossRefPubMed

17.

Burkhalter, J. E., Atkinson, T. M., Berry-Lawhorn, J., Goldstone, S., Einstein, M. H., Wilkin, T. J., et al. (2018). Initial development and content validation of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions. Value Health., 21(8), 984–992. https://doi.org/10.1016/j.jval.2018.01.018. PubMed PMID: 30098677; PubMed Central PMCID: PMC6093301.CrossRefPubMedPubMedCentral

18.

Atkinson, T. M., Palefsky, J., Li, Y., Webb, A., Berry, J. M., Goldstone, S., et al. (2019). Reliability and between-group stability of a health-related quality of life symptom index for persons with anal high-grade squamous intraepithelial lesions: An AIDS Malignancy Consortium Study (AMC-A03). Quality of Life Research, 28(5), 1265–9. https://doi.org/10.1007/s11136-018-2089-8. PubMed PMID: 30617704; PubMed Central PMCID: PMC6472969.CrossRefPubMedPubMedCentral

19.

Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., et al. (2006). Patient vs clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: Results of a questionnaire-based study. The Lancet Oncology, 7, 903–909. https://doi.org/10.1016/S1470-2045(06)70910-XCrossRefPubMed

20.

Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579. PubMed PMID: 8445433.CrossRefPubMed

21.

Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., et al. (2000). Assessing symptom distress in cancer patients: The M.D. Anderson symptom inventory. Cancer, 89(7), 1634–46. PubMed PMID: 11013380.CrossRefPubMed

22.

McArdle, J. J. (1996). Current directions in structural factor analysis. Current Directions in Psychological Science., 5, 11–18.CrossRef

23.

Hu, L., & Bentler, P. M. (1999). Cutoff criteria for fit indices in covariance structure analysis: Conventional criteria vs new alternatives. Structural Equation Modeling: A Multidisciplinary Journal, 6, 1–55.CrossRef

24.

Bentler, P. M. (1990). Comparative fit indexes in structural models. Psychological Bulletin, 107, 238–246.CrossRefPubMed

25.

Hair, J. F., Black, W. C., Babin, B. J., Anderson, R. E., & Tatham, R. L. (2009). Multivariate data analysis (7th ed.). Pearson Prentice Hall.

26.

Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory (3rd ed.). McGraw-Hill.

27.

Arbuckle, J. L. (2019). Amos (version 26.0) [computer program]. IBM SPSS.

28.

R Core Team. (2022). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. Retrieved from http://www.R-project.org

29.

Middel, B., & van Sonderen, E. (2002). Statistical significant change vs relevant or important change in (quasi) experimental design: Some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. International Journal of Integrated Care., 2, e15. https://doi.org/10.5334/ijic.65. PubMed PMID: 16896390; PubMed Central PMCID: PMC1480399.CrossRefPubMedPubMedCentral

30.

SAS Institute Inc. (2013). SAS/ACCESS® 9.4 interface to ADABAS: Reference. SAS Institute Inc.

31.

Atkinson, T. M., Dueck, A. C., Satele, D. V., Thanarajasingam, G., Lafky, J. M., Sloan, J. A., et al. (2020). Clinician vs patient reporting of baseline and postbaseline symptoms for adverse event assessment in cancer clinical trials. JAMA Oncology, 6(3), 437–9. https://doi.org/10.1001/jamaoncol.2019.5566. PubMed PMID: 31876902; PubMed Central PMCID: PMC6990818.CrossRefPubMed

32.

Basch, E., & Yap, C. (2021). Patient-reported outcomes for tolerability assessment in phase I cancer clinical trials. Journal of the National Cancer Institute, 113(8), 943–4. https://doi.org/10.1093/jnci/djab017. PubMed PMID: 33616647; PubMed Central PMCID: PMC8328974.CrossRefPubMedPubMedCentral

33.

Goddard, S. L., Templeton, D. J., Petoumenos, K., Jin, F., Hillman, R. J., Law, C., et al. (2019). Association of anal symptoms with anal high grade squamous intraepithelial lesions (HSIL) among men who have sex with men: Baseline data from the study of the prevention of anal cancer (SPANC). Cancer Epidemiology, 58, 12–6. https://doi.org/10.1016/j.canep.2018.10.009. PubMed PMID: 30439602.CrossRefPubMed

34.

Atkinson, T. M., Lynch, K. A., Vera, J., Olivares, N. M., Webb, A., Diamond, L. C., et al. (2022). Linguistic validation of the Spanish version of the anal cancer high-grade squamous intraepithelial lesions outcomes Research Health-Related Symptom Index (A-HRSI): AMC-A04. Journal of Patient-Reported Outcomes. https://doi.org/10.1186/s41687-022-00515-1. PubMed Central PMCID: PMC9552152.CrossRefPubMedPubMedCentral

35.

Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care., 41(5), 582–92. https://doi.org/10.1097/01.MLR.0000062554.74615.4C. PubMed PMID: 12719681.CrossRefPubMed

36.

Bennett, A. V., Dueck, A. C., Mitchell, S. A., Mendoza, T. R., Reeve, B. B., Atkinson, T. M., et al. (2016). Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health and Quality of Life Outcomes., 14, 24. https://doi.org/10.1186/s12955-016-0426-6.PubMedPMID:26892667;PubMedCentralPMCID:PMCPMC4759776CrossRefPubMedPubMedCentral

37.

Gwaltney, C. J., Shields, A. L., & Shiffman, S. (2008). Equivalence of electronic and paper-and-pencil administration of patient-reported outcome measures: A meta-analytic review. Value Health., 11(2), 322–333. https://doi.org/10.1111/j.1524-4733.2007.00231.x. PubMed PMID: 18380645.CrossRefPubMed

38.

Muehlhausen, W., Doll, H., Quadri, N., Fordham, B., O’Donohoe, P., Dogar, N., et al. (2015). Equivalence of electronic and paper administration of patient-reported outcome measures: a systematic review and meta-analysis of studies conducted between 2007 and 2013. Health and Quality of Life Outcomes., 13, 167. https://doi.org/10.1186/s12955-015-0362-x.PubMedPMID:26446159;PubMedCentralPMCID:PMC4597451CrossRefPubMedPubMedCentral

Titel: Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03
Auteurs: Thomas M. Atkinson
Shelly Lensing
Jeannette Y. Lee
Di Chang
Soo Young Kim
Yuelin Li
Kathleen A. Lynch
Andrew Webb
Susan M. Holland
Erica I. Lubetkin
Stephen Goldstone
Mark H. Einstein
Elizabeth A. Stier
Dorothy J. Wiley
Ronald Mitsuyasu
Isabella Rosa-Cunha
David M. Aboulafia
Shireesha Dhanireddy
Jeffrey T. Schouten
Rebecca Levine
Edward Gardner
Jeffrey Logan
Hillary Dunleavy
Luis F. Barroso
Gary Bucher
Jessica Korman
Benjamin Stearn
Timothy J. Wilkin
Grant Ellsworth
Julia C. Pugliese
Abigail Arons
Jack E. Burkhalter
David Cella
J. Michael Berry-Lawhorn
Joel M. Palefsky
Publicatiedatum: 05-04-2023
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 8/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-023-03391-4

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 8/2023

Ethical and practical considerations related to data sharing when collecting patient-reported outcomes in care-based child health research

A composite measure for patient-reported outcomes in orthopedic care: design principles and validity checks

Psychometric validation of the celiac disease-specific quality of life survey (CD-QOL) in adults with celiac disease in the United States

Development and validation of a measure of adolescent and young adult goal-based quality of life (MAYA-GQOL)

The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review

Physical and mental health of breast cancer patients and survivors before and during successive SARS-CoV-2-infection waves